Vineet Sankhla/X
Sep 8, 2026, 09:42
Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
Vineet Sankhla, Interventional Cardiologist Health New Zealand – Te Whatu Ora, shared a post on X:
“More bleeding with Prasu/Tica plus DOACs in AF patients undergoing PCI.
Clopidogrel may be safer choice in triple anti platelet therapy.
EPIDAURUS: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and ACS undergoing PCI.”
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP